FDA Approves TIGECYCLINE — Sandoz Inc

Sandoz Inc. has received FDA approval for its generic intravenous formulation of tigecycline, increasing therapeutic availability and competing against the branded product. This approval is expected to drive down costs for hospitals treating severe bacterial infections, potentially increasing overall utilization within the acute care segment.